medigraphic.com
Centro de Investigaciones Regionales Dr. Hideyo Noguchi, Universidad Autónoma de Yucatán

2008, Number 1

<< Back Next >>

Rev Biomed 2008; 19 (1)

Recurrent malaria to Plasmodium vivax, country of Cajigal, state of Sucre, Venezuela

Sojo-Milano M, Cáceres JL, Pizzo NN, Rojas J, Maldonado A, Rubio-Pulgar N, Campos E, Terán E, Pérez A

Language: Spanish
References: 29
Page: 3-15
PDF size: 230.10 Kb.


ABSTRACT

Introduction. Recurrent malaria modifies its local epidemiology and it is important to consider its systematic observation as a meaningful tool for the routine surveillance in endemic areas.
Objective. To assess some clinical and epidemiological features of recurrent Plasmodium vivax malaria cases receiving the WHO standard treatment in Cajigal municipality, Sucre state, Venezuelan Eastern malaria focus.
Material and methods. Fiftythree patients with uncomplicated vivax malaria in Cajigal municipality gave consent for receiving supervised medical treatment (chloroquine 25mg/kg over three days plus primaquine 0.25mg/Kg over a 14-day period) and being followed for six months within the mentioned endemic area. Giemsa-stained thin and thick blood smears were examined on recruitment day and on days 7, 14, 28, 42, 56, 70, 84, 112, 140 y 168, during which demographic, clinical and therapeutic information was recorded.
Results. 88.7% (47/53) completed the follow-up between 28 and 168 days. 27.7% (IC 95% 14.7-40.7) (13/47) had parasite recurrences (76.9% had one, 7.7% two and 15.4% up to three). 2.1% had a recurrent episode before day 45. The highest proportion of first episodes, 84.6% (11/13), occurred between days 54 and 80; 36.4% (4/11) presented between 54 and 56 days and 63.6% (7/11) between 70 and 80 days.
Conclusions. The systematic follow-up of malaria cases for at least six months may approach the discrimination of recurrence type by P. vivax in endemic areas, controlling drug quality, dosage, and compliance together with both cases and entomological surveillance changes.


REFERENCES

  1. World Health Organization,WHO. WHO guidelines for the treatment of malaria. WHO/HTM/MAL/2006.1108. Geneva: WHO Press; 2006.

  2. Baird JK. Chloroquine resistance in Plasmodium vivax. Minireview. Antimichrob Agents Chemother 2004; 48 (11):4057-83.

  3. Dua VK, Sharma VP. Plasmodium vivax relapses after 5 days of primaquine treatment, in some industrial complexes of India. An Trop Med Parasitol 2001; 95:655-9.

  4. Kitchener SJ, Auliff AM, Rieckmann KH. Malaria in the Australian Defense Force during and after participation in the International Force in East Timor (INTERFET) Med J Aust 2000; 173:583-5.

  5. Duarte EC, Pang LW, Ribeiro LC, Fernandes CJ. Association of subtherapeutic dosages of a standar drug regimen with failures in preventing relapses of vivax malaria. Am J Trop Med Hyg 2001; 65:471-6.

  6. White NJ. The assessment of antimalarial drug efficacy. Trends Parasitol. 2002; 18:458-464.

  7. Pukrittayakamee S, Vanijanonta S, Chantra A, Clemens R, White, NJ. Blood stage antimalarial efficacy of primaquine in Plasmodium vivax malaria. J Infect Dis 1994; 169 (4):932-5.

  8. Boulos M, Amato Nero V, Dutra AP, DiSanti SM, Shiroma M. Analise da freqüência de recaídas de malaria por Plasmodium vivax em regiao não endêmica, São Paulo, Brazil. Rev Inst Med Trop São Paulo 1991; 33:143-6.

  9. Villalobos-Salcedo JM, Tada MS, Kimura E, Menezes MJ, Pereira-da-Silva LH. In vivo sensitivity of Plasmodium vivax isolates from Rondônia (western Amazon region, Brazil) to regimens including chloroquine and primaquine. An Trop Med Parasitol 2000; 94(8):749-58.

  10. Arias AE, Corredor A. Low response of Colombian strains of Plasmodium vivax to classical antimalarial therapy. An Trop Med Parasitol 1989; 40:21-3.

  11. Pérez HA. La malaria por Plasmodium vivax (Grassi y Feletti, 1890) en los trópicos y los retos de la cura radical. Interciencia 2004; 29(9):490-5.

  12. Ministerio de Salud de Venezuela, Coordinación de Malaria de la Dirección General de Salud Ambiental-Unidad de Estadísticas. Boletines epidemiológicos 2000-2007.

  13. Sojo-Milano M. Socioeconomic, behavioural and environmental factors that account for the re-introduction and persistence of malaria in Sucre, Eastern Venezuela. Implications for malaria control. Upgrading Report. Londres: London School of Hygiene and Tropical Medicine; 2000.

  14. Organización Panamericana de la Salud, Oficina Sanitaria Panamericana, Oficina Regional de la Organización Mundial de la Salud. Evaluación de la eficacia terapéutica de los medicamentos para el tratamiento del paludismo por Plasmodium falciparum sin complicaciones en las Américas. Documento adaptado por un grupo de expertos reunidos en Manaus, Brasil. 1 al 5 de marzo de 1998.[OPS/HCP/HCT/113/98]. Original: Inglés.

  15. Red Amazónica para la Vigilancia de las Drogas Antimaláricas (RAVREDA) de la Organización Panamericana de la Salud/Oficina Sanitaria Panamericana, Oficina Regional de la Organización Mundial de la Salud, Unidad de Control de Enfermedades Transmisibles, División de Prevención y Control de Enfermedades, OPS/OMS; Center for Disease Control and Prevention & Iniciativa Amazónicas contra la Malaria, IAM (AMI por Amazon Malaria Initiative) de USAID (2003).Guía práctica para estudios in vivo de eficacia de los medicamentos antimaláricos en las Américas. [OPS/DPC/CD/240/03].Original:Español.

  16. World Health Organization WHO. Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria, 2003. Geneva. WHO/CDS/CSR/RMB/Doc ref no].

  17. Epi Info 6. Versión 6.04. Procesador de textos, base de datos y estadísticas para la Salud Pública. Center for Disease Control & Prevention (CDC) USA; World Health Organization, Geneva, Switzerland. 2001.

  18. Med Calc® Manual. Versión 8.0.0.0. Statistical software for Windows. Belgium. 2006.

  19. Bruce-Chwatt LJ. Essential Malariology. Second edition. Londres, Reino Unido:Heinemann Medical Books; 1986.

  20. Coatney GR, Cooper WC, Young MD. Studies in human malaria. XXX. A summary of 204 sporozoite-induced infections with the Chesson strain of Plasmodium vivax. J.Nat.Mal.Soc 1950; 9:381-96.

  21. Contacos PG, Collins WE, Jeffery GM, Krotoski WA, Howard WA. Studies on the characterization of Plasmodium vivax strains from Central America. Am J Trop Med Hyg 1972; 21(5):707-20.

  22. Cogswell FB. The hypnozoites and relapse in primatemalaria. Clin Microbiol Rev 1992; 5, 26-35.

  23. Coatney GR. Relapse in malaria–an enigma. J Parasitol 1976; 62:3-9.

  24. Krotoski WA. Discovery of the hypnpzoite and a new theory of malarial relapse. Trans R Soc Trop Med Hyg 1985; 79(1):1-11.

  25. Baird K, Rieckmann K. Can primaquine therapy for vivax malaria be improved? Trends Parasitol 2003;.19(3):115-20.

  26. Sojo-Milano M, Cáceres JL, Sojo-Milano E, Rondón L, González C, Rubio N. Conocimientos, prácticas y percepciones sobre malaria. Parroquia Yaguaraparo, Estado Sucre, Venezuela, 2004. Memorias de las XIV Jornadas Científicas “Dr. Arnoldo Gabaldon”. Instituto de Altos Estudios de Salud Pública “Dr. Arnoldo Gabaldon” 2007.

  27. Mendis K, Sina BJ, Marchesini P, Carter R. The neglected burden of Plasmodium vivax malaria. Am J Trop Med Hyg 2001;. 64:97-106.

  28. Rowland M, Durani N. Randomized controlled trials of 5- and 14 days primaquine therapy against relapses of vivax malaria in an Afghan refugee settlement in Pakistan. Trans R Soc Trop Med Hyg 1999; 93:641-43.

  29. Collins WE, Jeffery GM. Primaquine resistance in Plasmodium vivax. Am J Trop Med Hyg 1996; 55:243-49.




2020     |     www.medigraphic.com